Current and Future Trends in Treatment of Severe Retinopathy of Prematurity

被引：21
作者：
Wallace, David K. [1 ]
Wu, Katherine Y. [1 ,2 ]
机构：
[1] Duke Eye Ctr, Dept Ophthalmol & Pediat, Durham, NC 27710 USA
[2] Duke Univ, Sch Med, Durham, NC USA
来源：
CLINICS IN PERINATOLOGY | 2013年 / 40卷 / 02期
关键词：
Retinopathy of prematurity; Type; 1; Laser photocoagulation; Bevacizumab; Clinical trials; Side effects; INTRAVITREAL BEVACIZUMAB; CASE SERIES; THERAPY; INJECTION; EFFICACY; ROP;
D O I：
10.1016/j.clp.2013.02.005
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Treatment for retinopathy of prematurity (ROP) is indicated when type 1 disease is present. The Early Treatment for Retinopathy of Prematurity (ETROP) clinical trial established that laser treatment of severe ROP has a high rate of visual and anatomic success. Recently, anti-vascular endothelial growth factor (VEGF) drugs such as bevacizumab have been used in lieu of or in addition to laser treatment. Results are promising, but long-term outcomes and systemic side effects are unknown. Future studies are needed to determine whether anti-VEGF treatment is superior to laser and, if so, which drug and dose are safe and effective.
引用
收藏
页码：297 / +
页数：15
相关论文
共 23 条
  • [1] [Anonymous], 1990, ARCH OPHTHALMOL-CHIC, V108, P1408
  • [2] Intravitreal bevacizumab for retinopathy of prematurity as first line or rescue therapy with focal laser treatment. A case series
    Dani, Carlo
    Frosini, Saverio
    Fortunato, Pina
    Bertini, Giovanna
    Pratesi, Simone
    Pollazzi, Liliana
    Caputo, Roberto
    La Torre, Agostino
    [J]. JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2012, 25 (11) : 2194 - 2197
  • [3] Are we there yet? Bevacizumab therapy for retinopathy of prematurity
    Darlow, Brian A.
    Ells, Anna L.
    Gilbert, Clare E.
    Gole, Glen A.
    Quinn, Graham E.
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 2013, 98 (02): : F170 - F174
  • [4] Dorta Paola, 2010, Retina, V30, pS24, DOI 10.1097/IAE.0b013e3181ca1457
  • [5] Good WV, 2010, ARCH OPHTHALMOL-CHIC, V128, P663, DOI 10.1001/archophthalmol.2010.72
  • [6] Good WV, 2003, ARCH OPHTHALMOL-CHIC, V121, P1684
  • [7] Intravitreal Bevacizumab for Retinopathy of Prematurity
    Harder, Bjoern C.
    von Baltz, Stefan
    Jonas, Jost B.
    Schlichtenbrede, Frank C.
    [J]. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2011, 27 (06) : 623 - 627
  • [8] Reactivation of Retinopathy of Prematurity After Bevacizumab Injection
    Hu, Jennifer
    Blair, Michael P.
    Shapiro, Michael J.
    Lichtenstein, Steven J.
    Galasso, John M.
    Kapur, Rashmi
    [J]. ARCHIVES OF OPHTHALMOLOGY, 2012, 130 (08) : 1000 - 1006
  • [9] Kim H, 2009, MOL VIS, V15
  • [10] Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study
    Kusaka, S.
    Shima, C.
    Wada, K.
    Arahori, H.
    Shimojyo, H.
    Sato, T.
    Fujikado, T.
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2008, 92 (11) : 1450 - 1455
123